Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 3, 2013, Pages 304-310

  Molleston, Jean P ^a   Mellman, William ^b   Narkewicz, Michael R ^c   Balistreri, William F ^d   Gonzalez Peralta, Regino P ^e   Jonas, Maureen M ^f   Lobritto, Steven J ^g   Mohan, Parvathi ^h   Murray, Karen F ⁱ   Njoku, Dolores ^j   Rosenthal, Philip ^k   Barton, Bruce A ^l   Talor, Monica V ^j   Cheng, Irene ^m   Schwarz, Kathleen B ^j   Haber, Barbara A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e University of Florida and UF Health Shands Children s Hospital   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Department of Medicine   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ Division of Gastroenterology and Hepatology   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^m Clinical Trials & Surveys Corp   (United States)

more..

Author keywords

autoimmune; complications; diabetes; hypothyroid; pediatrics; therapy; viral hepatitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN ANTIBODY; MICROSOME ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CONTROLLED STUDY; DIABETES MELLITUS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; KIDNEY MICROSOME; LIVER MICROSOME; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RIBAVIRIN; UNITED STATES;

EID: 84874891118     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182774cae     Document Type: Article

References (29)

1. Jamil KM, Leedman PJ, Kontorinis N, et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 2009; 24:1017-23
2. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008;28:39-46
3. Bayraktar Y, Bayraktar M, Gurakar A, et al. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: The role of interferon in the development of autoimmune diseases. Hepatogastroenterology 1997; 44:417-25
4. Durante-Mangoni E, Iardino P, Resse M, et al. Silent celiac disease in chronic hepatitis C: Impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004;38:901-5
5. Elefsiniotis IS, Pantazis KD, Fotos NV, et al. Late onset autoimmune thrombocytopenia associated with pegylated interferon-Alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol 2006;21:622-3
6. Sykia A, Gigi E, Sinakos E, et al. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-A and ribavirin. J Gastrointest Liver Dis 2009;18:118-9
7. Vezali E, Elefsiniotis I, Mihas C, et al. Thyroid dysfunction in patients with chronic hepatitis C: Virus- or therapy-related? J Gastroenterol Hepatol 2009;24:1024-9
8. Dabrowska MM, Panasiuk A, Flisiak R. Thyroid dysfunction in antiviral therapy of chronic hepatitis C. Hepatogastroenterology 2010;57: 826-31
9. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4
10. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8
11. Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al. Design of the PEDS-C trial: Pegylated interferon /- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007;4:661-73
12. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79:47-56
13. Gregorio GV, Pensati P, Iorio R, et al. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;112:471-6
14. Bortolotti F, Muratori L, Jara P, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003;142:185-90
15. Frenzel C, Herkel J, Luth S, et al. Evaluation of F-Actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006; 101:2731-6
16. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8
17. Bortolotti F, Vajro P, Balli F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996;25:614-20
18. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26:561-6
19. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9
20. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995;22:1374-8
21. Piquer S, Hernandez C, Enriquez J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. J Lab Clin Med 2001;137:38-42
22. Di Cesare E, Previti M, Russo F, et al. Interferon-Alpha therapy may induce autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996;41:1672-7
23. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8
24. Kulmala P, Rahko J, Savola K, et al. Stability of autoantibodies and their relation to genetic and metabolic markers of type I diabetes in initially unaffected schoolchildren. Diabetologia 2000;43:457-64
25. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011;57:168-75
26. Chan WB, Chow CC, Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med 2003;96:481-5
27. Gelu-Simeon M, Burlaud A, Young J, et al. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009;15:328-33
28. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10
29. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52: 501-7